Low Dose Aspirin Studied With the AggreGuide

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Edward R. Teitel, M.D., Aggredyne, Inc.
ClinicalTrials.gov Identifier:
NCT01603966
First received: May 21, 2012
Last updated: July 14, 2012
Last verified: July 2012
  Purpose

This study is to determine whether the AggreGuide platelet aggregometer can discern the effect of low dose aspirin on subjects platelet aggregation using arachidonic acid as the agonist.


Condition
Platelet Aggregation

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Low Dose Aspirin Study With the AggreGuide

Resource links provided by NLM:


Further study details as provided by Aggredyne, Inc.:

Biospecimen Retention:   None Retained

whole blood


Enrollment: 13
Study Start Date: April 2012
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

community sample

Criteria

Inclusion Criteria:

  • adults

Exclusion Criteria:

  • aspirin contraindications
  • anticoagulants
  • aspirin past week
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01603966

Locations
United States, Texas
Aggredyne, Inc.
Houston, Texas, United States, 77099
Sponsors and Collaborators
Edward R. Teitel, M.D.
Investigators
Principal Investigator: Edward R. Teitel, MD Aggredyne, Inc.
  More Information

No publications provided

Responsible Party: Edward R. Teitel, M.D., CEO, Aggredyne, Inc.
ClinicalTrials.gov Identifier: NCT01603966     History of Changes
Other Study ID Numbers: Val-030
Study First Received: May 21, 2012
Last Updated: July 14, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Aggredyne, Inc.:
platelet
aggregation
aspirin
inhibition
reactivity

Additional relevant MeSH terms:
Aspirin
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antipyretics
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 20, 2014